Curative NHP FVIII data fuels hemophilia A gene-editing bet, but human proof is still a 2027 question

Updated 36d ago

Metagenomi is a clinical-stage company developing a gene-editing therapy for hemophilia A that is not yet approved.

MGX-001, a proprietary CRISPR-based gene editing therapy for hemophilia A, showed curative Factor VIII activity in non-human primates, a signal that distinguishes it from factor replacement but remains unvalidated in humans. The thesis resolves on whether FIH data confirms durable FVIII correction at tolerable safety, converting preclinical promise into clinical proof-of-concept. Cash of $121M funds operations through Q4 2027, covering IND submission and FIH initiation, but not a meaningful efficacy readout.

Status

Intact

Conviction

Current Thesis Drivers

Curative FVIII activity demonstrated in NHP preclinical studies
Pre-IND meeting completed with regulatory advancement support
No human efficacy data — FIH not yet initiated
$121M cash covers IND and FIH start, not efficacy readout

What could change the thesis?

Q4 2026 IND clearance: greenlit accelerates FIH, rejection delays and pressures runway
FIH 2027 safety readout: clean safety advances thesis, signal ends it
Financing before efficacy data: dilutive raise extends runway, failure to raise forces cuts

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

3 programs · 5 catalysts

Stress Test